Stryker price target raised to $275 from $257 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Stryker to $275 from $257 and keeps a Hold rating on the shares. The company’s Q4 organic revenue growth was "solid" with earnings upside despite another miss on margins, the analyst tells investors in a research note. Medical capital drove a good amount of the outperformance, which may not be viewed as sustainable, but earnings estimates are going up and stock strength should follow, the firm adds.